RADOTINIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C27H21F3N8O
Molecular Weight	530.5049
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cc1ccc(cc1Nc2nccc(-c3cnccn3)n2)C(=Nc4cc(cc(c4)-n5cc(C)nc5)C(F)(F)F)O

InChI

InChIKey=DUPWHXBITIZIKZ-UHFFFAOYSA-N

InChI=1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37)

HIDE SMILES / InChI

Molecular Formula	C27H21F3N8O
Molecular Weight	530.5049
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://healthcare.utah.edu/huntsmancancerinstitute/research/labs/deininger/_pdfs/2015-Zabriskie-OHare-Radotinib-CML-plus-supplement.pdf
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24705186

Radotinib (Supect) was developed and approved in Korea as a second-line Chronic Myeloid Leukemia treatment. The drug supresses cancer cells proliferation by inhibitiing BCR-ABL1 kinase which is a driver of Philadelphia chromosome-positive (Ph+) leukemia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bcr/Abl fusion protein 9 Target ID: CHEMBL2096618 Sources: https://healthcare.utah.edu/huntsmancancerinstitute/research/labs/deininger/_pdfs/2015-Zabriskie-OHare-Radotinib-CML-plus-supplement.pdf	Inhibitor 3315		34.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic myeloid leukemia 11 Sources: https://healthcare.utah.edu/huntsmancancerinstitute/research/labs/deininger/_pdfs/2015-Zabriskie-OHare-Radotinib-CML-plus-supplement.pdf	Primary		Approved 4033	SUPECT Approved Use Second-line treatment of Chronic Myeloid Leukemia. Launch Date 1.32537595E12

PubMed

Title	Date	PubMed
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.	2014 Jul	24705186
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.	2015 Sep	25676420

Patents

Sample Use Guides

In Vivo Use Guide

Take 300 mg or 400 mg twice daily.

Route of Administration: Oral

In Vitro Use Guide

Acute myeloid leukemia NB4, HL60, KASUMI-1 and THP-1 cells were incubated with various concentrations of radotinib (0, 1,10, and 100 uM) for 72 h at 37C. At 100 uM NB4 cells growth was inhibited to 18%.

Substance Class	Chemical Created by `admin` on `Sat Jun 26 13:55:49 UTC 2021` Edited by `admin` on `Sat Jun 26 13:55:49 UTC 2021`
Record UNII	I284LJY110
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RADOTINIB

Official Name

English

RADOTINIB [WHO-DD]

Common Name

English

RADOTINIB [MI]

Common Name

English

IY5511

Code

English

4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-TRIFLUOROMETHYLPHENYL)-3-(4-(PYRAZIN-2-YL)PYRIMIDIN-2-YLAMINO)BENZAMIDE

Systematic Name

English

BENZAMIDE, 4-METHYL-N-(3-(4-METHYL-1H-IMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-(2-PYRAZINYL)-2-PYRIMIDINYL)AMINO)-

Systematic Name

English

RADOTINIB [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1967